Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Buy
54
TYRA Quote, Financials, Valuation and Earnings
Last price:
$11.21
Seasonality move
:
7.27%
Day range:
$10.20 - $10.95
52-week range:
$6.42 - $29.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.79x
Volume:
222.9K
Avg. volume:
392.6K
1-year change:
-49.33%
Market cap:
$580.7M
Revenue:
--
EPS (TTM):
-$1.63
Analysts' Opinion
-
Consensus RatingTyra Biosciences has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $30.14, Tyra Biosciences has an estimated upside of 176.03% from its current price of $10.92.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $28.00 representing 100% downside risk from its current price of $10.92.
Fair Value
-
According to the consensus of 6 analysts, Tyra Biosciences has 176.03% upside to fair value with a price target of $30.14 per share.
TYRA vs. S&P 500
-
Over the past 5 trading days, Tyra Biosciences has overperformed the S&P 500 by 6.89% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Tyra Biosciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Tyra Biosciences has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Tyra Biosciences reported revenues of --.
Earnings Growth
-
Tyra Biosciences has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Tyra Biosciences reported earnings per share of -$0.47.
Enterprise value:
261.8M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-3.55x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$58.4M | -$87.9M | -$113.7M | -$22.3M | -$31.9M | |
| EBITDA | -$58.1M | -$87.5M | -$113.2M | -$22.2M | -$31.7M | |
| Diluted EPS | -$1.25 | -$1.68 | -$1.63 | -$0.35 | -$0.47 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $294M | $246.7M | $390.8M | $324.6M | |
| Total Assets | -- | $299M | $255.1M | $404.7M | $343.5M | |
| Current Liabilities | -- | $4.9M | $3.7M | $8.7M | $14.2M | |
| Total Liabilities | -- | $7.8M | $6.3M | $14.9M | $19.9M | |
| Total Equity | -- | $291.2M | $248.8M | $389.9M | $323.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$51.2M | -$62.3M | -$73.2M | -$22M | -$25.5M | |
| Cash From Investing | -$361K | -$126.5M | -$84.5M | $18.1M | $32M | |
| Cash From Financing | $770K | $201.5M | $4M | $200.3M | $2.2M | |
| Free Cash Flow | -$51.6M | -$63.2M | -$73.7M | -$22.2M | -$25.5M | |
TYRA
Sector
Market Cap
$580.7M
$34.4M
Price % of 52-Week High
36.89%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-49.33%
-37.36%
Beta (5-Year)
--
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$10.27
200-day SMA
Sell
Level
$13.55
Bollinger Bands (100)
Buy
Level
8.93 - 11.03
Chaikin Money Flow
Buy
Level
717.2K
20-day SMA
Buy
Level
$9.89
Relative Strength Index (RSI14)
Buy
Level
59.61
ADX Line
Buy
Level
35.02
Williams %R
Sell
Level
-4.0609
50-day SMA
Buy
Level
$9.88
MACD (12, 26)
Buy
Level
2.87
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Neutral
Level
1.7M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (2)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company’s in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Stock Forecast FAQ
In the current month, TYRA has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TYRA average analyst price target in the past 3 months is $30.14.
-
Where Will Tyra Biosciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that Tyra Biosciences share price will rise to $30.14 per share over the next 12 months.
-
What Do Analysts Say About Tyra Biosciences?
Analysts are divided on their view about Tyra Biosciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Tyra Biosciences is a Sell and believe this share price will drop from its current level to $28.00.
-
What Is Tyra Biosciences's Price Target?
The price target for Tyra Biosciences over the next 1-year time period is forecast to be $30.14 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is TYRA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Tyra Biosciences is a Buy. 6 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of TYRA?
You can purchase shares of Tyra Biosciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Tyra Biosciences shares.
-
What Is The Tyra Biosciences Share Price Today?
Tyra Biosciences was last trading at $11.21 per share. This represents the most recent stock quote for Tyra Biosciences. Yesterday, Tyra Biosciences closed at $10.92 per share.
-
How To Buy Tyra Biosciences Stock Online?
In order to purchase Tyra Biosciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
How High Can SharkNinja Stock Go?
If you know popular consumer appliance brands Shark and Ninja,…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 4.98% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 0.73% over the past day.
Sell
42
VLCN alert for Jul 17
Volcon [VLCN] is up 229.89% over the past day.
